Rating Change
Barclays reiterated its Overweight rating on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) on October 06, 2026.
reiterateNASDAQ:XERS
Barclays Reiterates Overweight Rating on Xeris Biopharma Holdings, Inc. (XERS)
Barclays reiterated its Overweight rating on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) on October 06, 2026.
At publication ·
What changed
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $10.07
- Market capitalization
- $1.2B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on Xeris Biopharma on October 6, 2026, indicating positive analyst sentiment.
Market Context
Xeris Biopharma Holdings, Inc. operates in the Healthcare sector. The stock currently trades at $10.07 with a market capitalization of $1.2B.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Xeris Biopharma Holdings, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Xeris Biopharma Holdings, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 06, 2026 | Barclays | Overweight | N/A |
| Sep 10, 2026 | Leerink Partners | Outperform | N/A |
| Aug 20, 2026 | Barclays | Overweight | N/A |
| Mar 02, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jan 09, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View XERS Stock Page
Frequently Asked Questions
What does the Overweight rating mean for XERS?
A rating of Overweight from Barclays reflects the analyst's outlook on Xeris Biopharma Holdings, Inc. (NASDAQ:XERS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the XERS forecast page.